Table 1.

Characteristics of individual studies of the INHANCE consortium pooled analysis, including information on caffeinated coffee, decaffeinated coffee, or tea drinking

Study reference*Study locationRecruitment periodSource (cases/controls)Information onParticipation rate of cases and controls (%)Age eligibility (y)Cancer of total oral cavity/pharynxCancer of larynxControls
Caffeinated coffeeDecaffeinated coffeeTeaOral cavityOropharynx/hypopharynxOral cavity/pharynx NOS
Europe
    (32)Italy (Milan)1984–1989Hospital/hospitalYesYesYes95–95<804861652421,531
    (33)France1987–1992Hospital/hospitalYesNoYes95–95Not reported4910218154234
    (34, 40)Italy multicenter (Aviano, Milan, Latina)1990–2005Hospital/hospitalYesYesYes>95–9518–80209502904602,716
    (35)Switzerland (Lausanne)1991–1997Hospital/hospitalYesYesYes95–95<801382477124883
North America
    (36)United States (Los Angeles)1999–2004Cancer registry/neighborhoodYesYesYes49–67.518–6553173112901,040
    (37)United States (Boston)1999–2003Hospital/residential recordsYesYesYes88.7–87.3≥1813929143111659
    (1)U.S. multicenter (Atlanta, Los Angeles, San Francisco, New Jersey)1983–1984Cancer registry/random digit dialing-healthcare financingYesNoYes75–7618–793865102181,268
    (38)Memorial Sloan-Kettering Cancer Center New York1992–1994Hospital/hospitalYesYesYes95–95>207526243176
Central America
    (39)Puerto Rico1992–1995Cancer registry/residential recordsYesNoYes71–8321–7994200521521
Total subjects1,1912,1126121,2249,028
  • *Representative publications in which study methods are available.

  • The total number of controls for the analyses on laryngeal cancer was 7,239, as two studies were not included (1, 39).

  • Participation rate was not formally assessed.